Picture of Biomerieux SA logo

BIM — Biomerieux SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: Biomerieux H1 Organic Sales Growth EUR 1.97 Bln, Adjusts Mid-Term Guidance

BRIEF-Biomerieux H1 Organic Sales Growth EUR 1.97 Bln, Adjusts Mid-Term Guidance

- Biomerieux SA BIOX.PA:

  • 0.2% ORGANIC SALES GROWTH IN H1 26, AT EUR 1,965 MILLION

  • Q2 2026 SALES TOTALED EUR 981 MILLION, WITH SOLID ORGANIC GROWTH AT +5%,

  • H1 CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEM (CEBIT) AT €313 MILLION

  • H1 NET INCOME (GROUP SHARE) AMOUNTED TO EUR 226 MILLION, UP 41% COMPARED TO H1 2025

  • H1 ADJUSTED EPS OF €1.99

  • FREE CASH-FLOW GENERATION UP 76% IN H1 2026 VERSUS H1 2025

  • BIOMÉRIEUX CONFIRMS ITS 2026 GUIDANCE

  • BIOMÉRIEUX IS ADJUSTING ITS MIDTERM FINANCIAL OUTLOOK.

  • FOR 2027 AND 2028, BIOMÉRIEUX IS AIMING AT DELIVERING +3% TO +6% ORGANIC ANNUAL SALES GROWTH (VERSUS “7% CAGR 2024/2028” PREVIOUSLY)

  • FOR 2027 AND 2028, BIOMÉRIEUX IS AIMING AT DELIVERING ORGANIC ANNUAL CEBIT GROWTH HIGHER THAN ORGANIC SALES GROWTH (VERSUS "AT LEAST +10%" PREVIOUSLY)

Source text: [here]

Further company coverage: BIOX.PA


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48587696600;;))

Recent news on Biomerieux SA

See all news